Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses

Therapeutic Drug Monitoring

Volumn 31, Issue 4, 2009, Pages 451-456

  Kamar, Nassim ^a   Marquet, Pierre ^b,c   Gandia, Peggy ^d   Muscari, Fabrice ^a   Lavayssière, Laurence ^a   Esposito, Laure ^a   Guitard, Joelle ^a   Canivet, Cindy ^a   Peron, Jean Marie ^d   Alric, Laurent ^d   Suc, Bertrand ^d   Saint Marcoux, Franck ^b,c   Rostaing, Lionel ^a,d  

^a CHU RANGUEIL   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d CHU PURPAN   (France)

Author keywords

Adjusted dose; Area under the curve; Liver transplantation; Lymphoglobulins; Mycophenolate mofetil; Steroid free regimen

Indexed keywords

COTRIMOXAZOLE; DIPHENHYDRAMINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; PREDNISOLONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HEPATOBILIARY SYSTEM INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER GRAFT REJECTION; LYMPHOMA; MALE; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; SURVIVAL RATE; TREATMENT DURATION;

ADULT; AGED; CLINICAL PROTOCOLS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; REJECTION (PSYCHOLOGY); TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68449083304     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181aa776e     Document Type: Article

References (15)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
2. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
3. Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl. 2004;10:492-502.
4. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154.
5. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
6. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27:354-361.
7. Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation. 2006;81:541-546.
8. Venkataramanan R, Shaw LM. Therapeutic monitoring of mycophenolic acid in liver transplant patients. Liver Transpl. 2004;10:503-505.
9. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503.
10. Pisupati J, Jain A, Burckart G, et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol. 2005;45:34-41.
11. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
12. Nair S, Loss GE, Cohen AJ, et al. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation. 2006;81:620-622.
13. Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl. 2001;7:693-697.
14. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation. 2003;75:1396-1399.
15. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplation. Kidney International. 2002;62:1060-1067.